APA

Thomas B. M., Smith C., Evans J., Button M. R., Kumar S., Palaniappan N., Staffurth J., Tanguay J. S. & Lester J. F. (20140905). Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy. : Medical oncology (Northwood, London, England).

Chicago

Thomas Betsan M, Smith Christian, Evans Jessica, Button Michael R, Kumar Satish, Palaniappan Nachi, Staffurth John, Tanguay Jacob S and Lester Jason F. 20140905. Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy. : Medical oncology (Northwood, London, England).

Harvard

Thomas B. M., Smith C., Evans J., Button M. R., Kumar S., Palaniappan N., Staffurth J., Tanguay J. S. and Lester J. F. (20140905). Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy. : Medical oncology (Northwood, London, England).

MLA

Thomas Betsan M, Smith Christian, Evans Jessica, Button Michael R, Kumar Satish, Palaniappan Nachi, Staffurth John, Tanguay Jacob S and Lester Jason F. Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy. : Medical oncology (Northwood, London, England). 20140905.